1. Vardiman JBR, Arber DA, et al. Introduction and overview of the classification of myeloid neoplasms. In: Swerdlow SCE, Harris NL, editors. International Agency for Research on Cancer, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Geneva: World Health Organization; 2008. p. 18–30.
2. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91:1566–8.
3. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati MA, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117:2690–6.
4. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–7.
5. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52.